1
STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2 STATinMED Research, Ann Arbor, MI, USA, 3 STATinMED Research / Brigham and Women's Hospital, Ann Arbor, MI, USA OBJECTIVES: Health care claims databases do not contain information about disease severity. The goal of this study was to develop a severity index for rheumatoid arthritis (SIFRA) for private health care claims data using a previously developed claims-based index from the Veteran's Administration (VA) Health System and rheumatoid arthritis medical records-based index of severity (RARBIS). METHODS: We extracted the following variables related to rheumatoid arthritis from the claims data: total number of synthetic disease-modifying anti-rheumatic drugs (DMARDs), total number of biological DMARDs, tests for C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) ordered, rehabilitation visits, rheumatology visits, Felty's syndrome and Sjorgen's syndrome, pulmonary, soft tissue nodules, joint surgery, number of platelet counts and chemical panels ordered, and rheumatoid factors testing. A linear regression model was used to create the severity score. The severity score was compared with RARBIS and currently-used comorbidity scores to proxy severity in outcomes research studies related with rheumatoid arthritis. RESULTS: According to the Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), log likelihood function, R-squared values and average squared prediction error, SIFRA performed better than RARBIS, Charlson Comorbidity Score (CCI), Elixhauser comorbidity score and Chronic disease score. Spearman correlation with RARBIS was 0.65 and significant. However, the correlation with the Charlson Comorbidity Index (0.1, p = 0.6521), Elixhauser Index (0.15, p = 0.5312) and Chronic disease score (0.13, p = 0.6011) were low and insignificant. CONCLUSIONS: Controlling disease severity is crucial in retrospective studies. Comorbidity scores are inadequate to be proxy variable. SIFRA, at least for rheumatoid arthritis, controls for disease severity better than any other commonly used measure. To determine if switching from select branded to generic equivalent antiepileptic drug (AED) in patients with epilepsy is associated with adverse outcomes or with utilization changes that may proxy for adverse outcomes. METHODS: A retrospective cohort study using a large health insurance plan claims database was undertaken comparing patients with ICD-9-CM codes of epilepsy or non-febrile convulsions who switched from brand to generic equivalent AED after 6 months (switch cohort) to those who remained on the brand (non-switch cohort). Potential non-switch subjects were matched 1:1 to 745 phenytoin switch patients, 995 lamotrigine switch patients and 399 divalproex switch patients. Outcomes measured included the event rate ratio (ERR) of the composite of all-cause emergency department (ED) visits or hospitalizations and the incidence rate ratio (IRR) of discontinuation of the index AED, change in dose of index AED or addition of another AED. RESULTS: The switch vs. non-switch cohorts did not demonstrate differences in ED visits or hospitalizations for the studied AEDs (ERR for phenytoin 0.96, 95% CI 0.80-1.16; ERR for lamotrigine 0.97, 95% CI 0.80-1.17; ERR for divalproex 0.83, 95% CI 0.66-1.06). Compared with non-switchers, the phenytoin switch cohort had greater incidence of AED utilization changes (IRR 1.85, 95% CI 1.50-2.29). Lamotrigine and divalproex showed no differences in AED utilization between the switchers and nonswitchers (IRR for lamotrigine 1.00, 95% CI 0.84-1.19; IRR for divalproex 1.02, 95% CI, 0.88-1.42). CONCLUSIONS: Lamotrigine or divalproex brand to generic switching was not associated with increased incidence of ED visits or hospitalizations or utilization changes compared with patients remaining on the branded product. Brand to generic switching of phenytoin was not associated with an increase in ED visits or hospitalizations but was associated with greater numbers of index drug discontinuations, dose changes or therapy augmentations.
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PND2 THE VALUE OF A PREDICTIVE DIAGNOSTIC BLOOD TEST IN MULTIPLE SCLEROSIS (MS)
Van Hout BA 1 , Botteman M 2 , Dukler A 3 1 University of Sheffield, Sheffield, UK, 2 Pharmerit North America, LLC, Bethesda, MD, USA, 3 Glycominds Ltd., Lod, Israel OBJECTIVES: To assess the cost effectiveness of gMS®Pro EDSS, a test designed to identify MS patients with a high likelihood of progressing fast and in need of more aggressive treatment. METHODS: A literature-based discrete-event simulation follows patients visiting their physicians at defined EDSS score deteriorations. At each visit, 4 therapies are considered: three less aggressive/less expensive therapies (assumed monthly cost of $2,000/patient) and a more aggressive/more expensive therapy (assumed monthly cost of $3,000/patient) associated with severe side effects. The more agressive therapy is only considered cost effective in fast deteriorating patients. The expected cost effectiveness of each therapy was calculated using a Markov model (using EDSS scores as health states) and applying a Bayesian updating process considering the likelihood that the patient is "fast deteriorating" and/or responds to therapy. The model compares patients' costs and quality of life when the gMS®Pro EDSS test is used vs. when it is not. The estimated sensitivity and specificity of gMS®Pro EDSS were 65.18% and 84.09%, respectively based on clinical trail results. The costs of all non-medication costs were based on Kobelt et al. RESULTS: Using the test, in comparison to not using the test, in a MS population containing 25% of patients who progress fast results in more frequent (25.18% vs. 24.24%) and earlier (2.24 years on average) use of aggressive therapy. The test is estimated to result in a gain of 0.11 QALY's and to be economically dominant up to a price of $2640 (cost of medication is estimated to increase by $2984 which is offset by savings of $2704 of other direct medical costs and $2920 of production losses). CONCLUSIONS: The gMS®Pro EDSS is likely to be a cost effective addition in the identification of the optimal therapy for MS patients. Patients with and without GID were matched by age, gender, comorbidities, and treatment regime. Their respective emerging health outcomes were followed-up for two years. Outcomes were defined on the basis of a literature review and included neuropsychiatric, motor, urogenital disturbances, health care utilization and related costs. RESULTS: In the datacut, GID incidence among patients with PD increased over time to stabilize at 75% at 92 months. 485 patients with PD and GID were matched to 485 controls with PD but without GID. GID was associated with significantly higher rates of neuropsychiatric and motor disorders, including psychosexual dysfunction (RR = 8, p = 0.05), anxiety (RR = 1.61, p < 0.01), depression (RR = 1.28, p = 0.03), ataxia (RR = 1.24, p = 0.03), pain (RR = 1.28, p < 0.01), movement disorders (RR = 1.39, p < 0.01), urinary incontinence (RR = 1.43, p = 0.02), and risk of fall (RR = 1.44, p = 0.04). ER admissions (ratio = 1.42, p < 0.01), number of concurrent drugs (ratio = 1.06, p = 0.04) and PD and non-PD health care costs (ratios = 1.13 and 1.12, p < 0.01 respectively) increased during the observation period in the GID patients. CONCLUSIONS: GID have a substantial deleterious effect on major PDrelated clinical and societal outcomes. Non oral formulations of PD drugs (apomorphine or L-dopa pumps or rotigotine) may offer a good opportunity to bypass gastrointestinal tract, and accordingly maximize patient response to treatment.
PND3 GASTROINTESTINAL DISORDERS IN PATIENTS WITH PARKINSON'S DISEASE: A DOUBLE-EDGED SWORD
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PND4 ESTIMATED COST SAVINGS WHEN TREATING RESTLESS LEGS SYNDROME (RLS) WITH GABAPENTIN ENACARBIL IN THE US
Allen R 1 , Bharmal M 2 , Manjunath R 3 , Calloway M 3 1 The Johns Hopkins Bayview Medical Center, Baltimore, MD, USA, 2 Quintiles, Falls Church, VA, USA, 3 GlaxoSmithKline, Research Triangle Park, NC, USA OBJECTIVES: Estimate total (direct plus indirect) cost savings with 1200 mg of gabapentin enacarbil (GEn), a new RLS therapy. For formulary access, new medications must often show cost savings of drug. Before approval, data are hard to generate. This study provides one way of generating estimated pre-launch cost savings per patient. METHODS: Two data sources are used: pooled efficacy results from two 12-week, randomized, double-blind, placebo-controlled trials (Protocol XP052 and XP053, Clinical Trials.gov NCT00298623 and NCT00365352) of GEn and resource use/ economic data from a 2007 community survey. The survey collected RLS-related office (physician, emergency room, hospital) laboratory tests, prescription and nonprescription medication use. Indirect costs came from the Work Productivity and Activity Impairment (WPAI) questionnaire. Severity class costs were derived by using the International Restless Legs Syndrome Questionnaire. Estimated savings were derived by applying the proportion of patients moving between severity categories to cost differences between those categories. RESULTS: A total of 191 patients received GEn and completed baseline/Week 12 assessments. From baseline to Week 12, 48.2% with moderate RLS severity moved to mild severity, 26.7% moved from severe to mild and 8.4% moved from severe to moderate. The mean (SD) 3-month direct RLS-related costs among mild, moderate, severe and very severe patients were $48.90 ($113.7), $108.60 ($210.2), $264.60 ($391.30) and $428.3 ($689.40) , respectively. Mean (SD) 3-month indirect costs due to RLS-related lost productivity were $460.20 ($838.20), $1462.50 ($2513.90 ), $3699.30 ($3471.60) among mild, moderate and severe patients (no very severe reported working). Using sensitivity analyses, the per-patient,
